Sunitinib and Combination Therapy Protocols

Sunitinib (Sutent^®) was a product of Pfizer (New York, NY, USA). Sunitinib was dissolved in sterile DMSO (Sigma-Aldrich, D8418-50ML) and further diluted in a culture medium. A maximal concentration of 0.1% DMSO in culture medium specific to each cell line or the co-cultures was allowed for any of the screened conditions and was used as a control (CTRL). Panobinostat, vorinostat, axitinib, and pictilisib were purchased, stored, and dissolved as previously described [37 (link),46 (link)]. The PVAP combination containing panobinostat (10 nM), vorinostat (0.1 µM), axitinib (0.02 µM), and pictilisib (2 μM) was freshly prepared before each experiment as previously reported [37 (link),46 (link)]. For further information, see Table S2.